Targeting Androgen Receptor in Breast Cancer: Enzalutamide as a Novel Breast Cancer Therapeutic
Technical Report,15 Aug 2015,14 Aug 2016
University of Colorado, Anschutz Medical Campu Aurora United States
Pagination or Media Count:
In breast cancers, the androgen receptor AR is more widely expressed than estrogen receptor alpha ER or the progesterone receptor PR 1, which are used as therapeutic targets and biomarkers, suggesting a potential role for AR in BC. To explore the function of AR in models of the three main subtypes of breast cancer ER positive, ER negative and Her2 , we are using anew-generation AR inhibitor, enzalutamide, which impairs nuclear localization of AR. This is a very different mode of action than previous generation anti-androgens such as bicalutamide Casodex, which is a competitive inhibitor of endogenous androgens that allows ligand-mediated nuclear localization of AR. Enzalutamide has shown success in the clinic in patients with late stage prostate cancer. The research in this proposal generates preclinical data testing whether inhibition of AR with enzalutamide will be effective in breast cancer and utilize preclinical models of the three main subtypes of breast cancer. Our goal is to determine if and how enzalutamide should be combined with currently used standard of care treatments in the three main types of breast cancer, with the primary objectives of the research being to guide the design of future clinical trials with enzalutamide.
- Medicine and Medical Research